head JofIMAB
Journal of IMAB - Annual Proceeding (Scientific Papers)
Publisher: Peytchinski Publishing Ltd.
ISSN: 1312-773X (Online)
Issue: 2019, vol. 25, issue4
Subject Area: Medicine
DOI: 10.5272/jimab.2019254.2775
Published online: 11 November 2019

Case reports

J of IMAB. 2019 Oct-Dec;25(4):2775-2780;
Tatyana TelbizovaORCID logo Corresponding Autoremail, Mariana ArnaoudovaORCID logo,
Department of psychiatry and medical psychology, Medical University - Varna, MHAT St. Marina - Varna, Bulgaria.

Synthetic corticosteroids are a widely used and highly effective group of drugs for the treatment of a number of diseases. They have the potential to induce a broad spectrum of psychotic disorders that are often misdiagnosed, underestimated and unpredictable.
Objective:  The aim of the present article is to report two cases of corticosteroid-related psychotic disorders.
The first case was a patient who has undergone allogeneic bone marrow transplantation, followed by an oral administration of prednisolone with an initial daily dose of 100 mg, subsequently reduced by 10 mg per week. Upon reaching a dose of 50 mg daily, the patient suddenly became psychomotor agitated, in an elevated mood, with ecstatic and megalomaniac experiences. Prednisolone treatment was discontinued, and olanzapine was initiated at doses of 10 mg/day and diazepam at 10 mg/night. Within 5 days, the described psychopathological symptoms were de-actualized, and the antipsychotic treatment was discontinued.
The second case was a patient who was on a supportive treatment of four accompanying autoimmune diseases with methylprednisolone 4 mg/day and developed anxiety-depressive symptoms. Administration of Milnacipran at a maintenance dose of 100 mg/day led to significant reductions in depression and anxiety.
Conclusion: Corticosteroids have a high potential to induce a wide range of mental disorders. Clinicians and patients should be aware of these adverse effects. Inability to stop the corticosteroid treatment in many cases requires the use of psychotropic medications. Both drug interactions and the potential side effects need to be taken into consideration.

Keywords: corticosteroid, psychosis, psychotic disorder,

pdf - Download FULL TEXT /PDF 516 KB/
Please cite this article as: Telbizova T, Arnaoudova M. Corticosteroids - (Un)predictable inducers of psychiatric disorders. J of IMAB. 2019 Oct-Dec;25(4):2775-2780. DOI: 10.5272/jimab.2019254.2775

Corresponding AutorCorrespondence to: Tatyana Telbizova, MD, Department of psychiatry and medical psychology, Medical University-Varna, MHAT "St. Marina"; 1, Hristo Smirnenski str., 9010Varna, Bulgaria; E-mail: ttelbizova@gmail.com

1. Paragliola RM, Papi G, Pontecorvi A, Corsello SM. Treatment with Synthetic Glucocorticoids and the Hypothalamus-Pituitary-Adrenal Axis. Int J Mol Sci. 2017 Oct 20;18(10) pii:E:2201. [PubMed] [Crosref]
2. Knezevic NN, Voronov D, Candido KD. The efficacy and safety of corticosteroids in the treatment of acute and chronic pain. SJAIT 2016; 38(5-6):129-136. [Crossref]
3. Schiff D, Lee EQ, Nayak L, Norden AD, Reardon DA, Wen PY. Medical management of brain tumors and the sequelae of treatment. Neuro Oncol. 2015 Apr;17(4):488-504. [PubMed]  [Crossref]
4. Yasir M, Sonthalia S. Corticosteroid Adverse Effects. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019 Mar 24. [PubMed]
5. Kusljic S, Manias E, Gogos A. Corticosteroid-induced psychiatric disturbances: It is time for pharmacists to take notice. Res Social Adm Pharm. 2016 Mar-Apr;12(2):355-60. [PubMed] [Crossref]
6. Wolkowitz OM, Rubinow D, Doran AR, Breier A, Berrettini WH, Kling MA. Prednisone effects on neurochemistry and behavior. Preliminary findings. Arch Gen Psychiatry.1990; 47(10):963-968.  [Crossref]
7. Herman JP, McKlveen JM, Ghosal S, Kopp B, Wulsin A, Makinson R, et al. Regulation of the Hypothalamic-Pituitary-Adrenocortical Stress Response. Compr Physiol. 2016 Mar 15;6(2):603-21. [PubMed] Crossref]
8. Carroll BJ, Iranmanesh A, Keenan DM, Cassidy F, Wilson WH, Veldhuis JD. Pathophysiology of hypercortisolism in depression: pituitary and adrenal responses to low glucocorticoid feedback. Acta Psychiatr Scand. 2011 Jun;125(6):478-91. [PubMed] [Crossref]
9. Brown WA, Johnston R, Mayfield D. The 24-hour dexamethasone suppression test in a clinical setting: Relationship to diagnosis, symptoms, and response to treatment. Am J Psychiatry. 1979 Apr;136(4В):543-7. [PubMed]
10. Lotrich FE. Inflammatory cytokine-associated depression. Brain Res. 2015 Aug 18;1617:113-25. [PubMed] [Crossref]
11. Arnaudova-Zhekova MD. [Introduction to advanced and late-age psychiatry.] University Publishing House of Medical University – Varna. 2015. p. 175-216. [in Bulgarian]
12. Achkova. [Psychiatry.] Znanie ООD. 1996. p. 90-97. [in Bulgarian]
13. Conner SH, Solomon SS. Psychiatric Manifestations of Endocrine Disorders. J Hum Endocrinol. 2017; 2:1-7. [Crossref]
14. Ward L, George J. Corticosteroid-induced psychosis in rheumatoid arthritis. Progress in Neurology and Psychiatry. 2016 Sept/Oct;20(5):13-15. [Crossref]
15. Ou G, Bressler B, Galorport G, Lam E, Ko HH, Enns R, et al. Rate of Corticosteroid-Induced Mood Changes in Patients with Inflammatory Bowel Disease: A Prospective Study. JCAG. 2018 Sept;1(3):99–106. [PubMed] [Crossref]
16. Fardet L, Petersen I, Nazareth I. Suicidal behavior and severe neuropsychiatric disorders following glucocorticoid therapy in primary care. Am J Psychiatry. 2012 May;169(5):491-7. [PubMed] [Crossref]
17. Ciriaco M, Ventrice P, Russo G, Scicchitano M, Mazzitello G, Scicchitano F, Russo E. Corticosteroid-related central nervous system side effects. J Pharmacol Pharmacother. 2013 Dec;4(Suppl 1):S94-8. [PubMed] [Crossref]
18. Manzo C, Serra-Mestres J, Castagna A, Isetta M. Behavioral, Psychiatric, and Cognitive Adverse Events in Older Persons Treated with Glucocorticoids. Medicines (Basel). 2018 Aug 1;5(3)pii:E82. [PubMed]  [Crossref]
19. Swinburn CR, Wakefield JM, Newman SP, Jones PW. Evidence of prednisolone induced mood change (‘steroid euphoria’) in patients with chronic obstructive airways disease. Br J Clin Pharmacol 1988 Dec;26(6):709-13. [PubMed] [Crossref]
20. Acute adverse reactions to prednisone in relation to dosage. Clin Pharmacol Ther. 1972 Sep-Oct;13(5):694-8. [PubMed] [Crossref]
21. Lewis DA, Smith RE. Steroid-induced psychiatric syndromes. A report of 14 cases and a review of the literature J Affect Disord. 1983 Nov;5(4):319-32. [PubMed] [Crossref]
22. Warrington TO, Bostwick JM. Psychiatric adverse effect of corticosteroids. Mayo Clin Proc. 2006 Oct;81(10):1361-7. [PubMed] [Crossref]
23. Hall R, Popkin M, Stickney S, Gardner ER. Presentation of the steroid psychoses. J Nerv Ment Dis.1979 Apr;167(4):229-36. [PubMed] [Crossref]
24. Fardet L, Nazareth I, Whitaker HJ, Petersen I. Severe neuropsychiatric outcomes following discontinuation of long-term glucocorticoid therapy: a cohort study. J Clin Psychiatry. 2013 Apr;74(4):e281-6. [PubMed]  [Crossref ]
25. Turner P. Clinical pharmacology in criminal cases: discussion paper. J R Soc Med. 1987 Jul;80(7):438-40. [PubMed] [Crossref]
26. Ling MH, Perry PJ, Tsuang MT. Side effects of corticosteroid therapy. Psychiatric aspects. Arch Gen Psychiatry. 1981 Apr;38(4):471-7. [PubMed] [Crossref]
27. Bolanos SH, Khan DA, Hanczyc M, Bauer MS, Dhanani N, Brown ES. Assessment of mood states in patients receiving long-term corticosteroid therapy and in controls with patient-rated and clinician-rated scales. Ann Allergy Asthma Immunol. 2004 May;92(5):500-5. [PubMed] [Crossref]
28. George ME, Sharma V, Jacobson J, Simon S, Nopper AJ. Adverse Effects of Systemic Glucocorticosteroid Therapy in Infants With Hemangiomas. Arch Dermatol. 2004 Aug;140(8):963-9. [PubMed]  [Crossref]
29. Benyamin RM, Vallejo R, Kramer J, Rafeyan R. Corticosteroid induced psychosis in the pain management setting. Pain Physician. 2008 Nov-Dec;11(6):917-20. [PubMed]
30. Robinson DE, Harrison-Hansley E, Spencer RF. Steroid psychosis after an intra-articular injection. Ann Rheum Dis. 2000  Nov;59(11):927. [PubMed] [Crossref]
31. Liu EY, Vasudev A. Mania induced by clarithromycin in a geriatric patient taking low-dose prednisone. Prim Care Companion CNS Disord. 2014;16(3). pii: PCC.14l01626. [PubMed] [Crossref]
32. Tenev V. Drug Interaction Guide in Psychiatry and General Practice. Iztok – Zapad ЕАD; 2008. p.109-128.
33. Chau SY, Mok CC. Factors predictive of corticosteroid psychosis in patients with systemic lupus erythematosus. Neurology. 2003 Jul 8;61(1):104-7. [PubMed] [Crossref]
34. International Classification of Diseases X revision. Bulgarian Psychiatric Association; 2008. p. 57-61.
35. Wada K, Yamada N, Sato T, Suzuki H, Miki M, Lee Y, Akiyama K, Kuroda S. Corticosteroidinduced psychotic and mood disorders: Diagnosis defined by DSM-IV and clinical pictures. Psychosomatics. 2001 Nov-Dec;42:461-6. [PubMed] [Crossref]
36. Stroup TS, Gray N. Management of common adverse effects of antipsychotic medications. World Psychiatry. 2018 Oct;17(3):341-356. [PubMed] [Crossref]
37. Dietch JT. Steroid psychosis and tricyclic antidepressants. Arch Gen Psychiatry. 1982 Feb;39(2):236. [Crossref]
38. Roxanas MG, Hunt GE. Rapid reversal of corticosteroid-induced mania with sodium valproate: a case series of 20 patients. Psychosomatics. 2012 Nov-Dec;53(6):575-81. [PubMed] [Crossref]
39. Falk WE, Mahnke MW, Poskanzer DC. Lithium prophylaxis of corticotropin-induced psychosis. JAMA. 1979 Mar 9;241(10):1011-2. [PubMed] [Crossref]
40. Pryce CR, Fontana A. Depression in Autoimmune Diseases. Curr Top Behav Neurosci. 2017; 31:139-154. [PubMed] [Crossref]
41. Siegmann E, Muller HHO, Luecke C, Philipsen A, Kornhuber J, Gromer TW. Association of Depression and Anxiety Disorders With Autoimmune Thyroiditis: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2018; 75(6):577–584. [PubMed] [Crosref].

Received: 21 May 2019
Published online: 11 November 2019

back to Online Journal